RBC Capital lowered the firm’s price target on Humana to $353 from $415 but keeps an Outperform rating on the shares after its Q1 results and updated outlook. While the management is taking 2025 adjusted EPS growth targets off the table for now, the company also stressed its continued commitment to margin improvement next year, indicating that pulling guidance does not signal that 2025 is a no-growth year, the analyst tells investors in a research note. RBC adds however that it is still cutting its FY25 EPS outlook for Humana to $20.28 from $23.87.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana Inc Reveals Quarterly Financial Performance and Projections
- Humana no longer believes $6-$10 of adjusted EPS growth is appropriate for 2025
- Humana backs FY24 adjusted EPS view ‘approximately’ $16.00, consensus $16.36
- Humana reports Q1 adjusted EPS $7.23, consensus $6.12
- Notable companies reporting before tomorrow’s open
